EMA Report Highlights Parallel Regulatory/HTA Consultations Among Achievements
Executive Summary
A report from the EMA summarizing the mid-term achievements of its Regulatory Science Strategy to 2025 covers health technology assessments and a range of other topics.
You may also be interested in...
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Additional Analyses Help Idorsia Secure English Funding For Chronic Insomnia Drug Quviviq
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.
Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.